Michel Cousineau (MBA) has over 35 years of experience in corporate and business development in the health care sector for emerging companies as well as with subsidiaries of large international biopharmaceutical companies. He brings a vast network of contacts throughout the industry at various level of management and with investment groups.
Manuel Rosa-Calatrava (Ph.D., INSERM Research Director) is deputy director of the VirPath laboratory, director of the joint laboratory Biovirsafe and co-funder of the Virnext spin-off and the start-up VirHealth. He is currently principal investigator of several research programs focusing on respiratory viruses and development of new antiviral strategies.
Olivier Terrier (Ph.D.) is a CNRS researcher in VirPath laboratory and co-funder of the start-up VirHealth. His work is focused on influenza and other respiratory viruses/host interactions, and the development of innovative approaches for the identification of molecules of interest.
Guy Boivin (M.D. Ph.D.) is professor of microbiology-immunology at Laval University and a senior researcher in virology at the « Research Center in Infectious Diseases » of the same University. He holds the only Canadian Research Chair on emerging viruses and antiviral resistance. He is particularly interested in diagnosis, pathogenesis and treatment of viral infections.
Andrés Pizzorno (Ph.D.) is a postdoctoral researcher in the VirPath laboratory and co-inventor of many patents. He works on the development, characterization and evaluation of in vitro/in vivo new therapeutic approaches directed against respiratory viruses.